A Second Independent Proxy Advisor, ISS, Recommends Promis Neurosciences Shareholders Vote for the Share Consolidation
For any questions, please contact ProMIS’ proxy solicitation agent, Laurel Hill Advisory Group at 1-877- 452-7184 (+1-416-304-0211 outside North America) or email email@example.com.
TORONTO, Ontario and CAMBRIDGE, Mass. , Nov. 17, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (the “Company”), is pleased to announce that a second independent, third party proxy advisory firm, Institutional Shareholder Services (“ISS”), has recommended that shareholders vote FOR the share consolidation at the upcoming special general meeting of shareholders (the “Special Meeting”) to be held on December 1, 2021.
In their report, ISS agrees the share consolidation is in the best interest of ProMIS and its shareholders and state that it “should enhance the long-term growth prospects of the company by broadening its financing alternatives. Continued low trading prices of the company’s shares can put them below investment grade for many institutions, limiting the potential capital base for the company and its prospects for raising new capital as needed”.
ProMIS’s board of directors UNANIMOUSLY recommends that shareholders
VOTE FOR the Share Consolidation Resolution
Reasons for the Share Consolidation
Subject to shareholder approval, the Board intends to proceed with the share consolidation in furtherance of a listing of the Company’s shares on a stock exchange in the United States.
The Company anticipates that the share consolidation may also result in certain additional benefits as a result of a higher post-consolidation market price for its Common Shares, including:
- enhancing the Company’s comparability against its peers on per share metrics;
- increasing the pool of investors to include those whose internal investment policies may prohibit or discourage them from purchasing stocks trading below a certain minimum price; and
- increasing analyst and broker interest as policies governing analysts and brokers may discourage following or recommending issuers with lower stock prices.
YOUR VOTE IS IMPORTANT- PLEASE VOTE TODAY
The proxy voting deadline is 9:00 a.m. (Pacific Time) on Monday, November 29, 2021
How to Vote
There are several ways to vote your shares. Due to the essence of time, Shareholders are encouraged to vote online or by telephone
|Registered Shareholders||Beneficial Shareholders|
|Common Shares held in own name and represented by a physical certificate or DRS.||Common Shares held with a broker, bank or other intermediary.|
|Telephone||1-866-732-8683||Dial the applicable number listed on the voting instruction form enclosed.|
|Return the voting instruction form in the enclosed postage paid envelope.||Return the voting instruction form in the enclosed postage paid envelope.|
Shareholders are encouraged to read the Management Proxy Circular, which can be found on SEDAR at www.sedar.com or on the Company’s website at https://promisneurosciences.com/special-meeting-of-shareholders/.
Registered Shareholders and duly appointed proxyholders will be able to attend, participate and vote at the Meeting online at https://meetnow.global/MHCMWKT. Such persons may then enter the Meeting by clicking “Shareholder” and enter your 15-digit control number or click on “Invitation Code” and enter your Invitation Code. Non-Registered Shareholders who have not appointed themselves to vote as proxyholder at the Meeting, may login as a guest, by clicking on “Guest” and complete the online form.
For Registered Shareholders. The control number located on the form of proxy (or in the email notification you received if you have previously consented to receiving shareholder materials via email) is the username.
For Duly Appointed Proxy Holders. A Shareholder who wishes to appoint a person other than the management nominee(s) identified in the form of proxy to attend, participate or vote at the Meeting (including a non-registered Shareholder who wishes to appoint themselves) must visit http://www.computershare.com/promis by 9:00 a.m. (Pacific Time) on November 29, 2021 and provide Computershare with their proxyholder’s contact information, so that Computershare may provide the proxyholder with a Username via email. Without a username, proxyholders will not be able to attend, participate or vote at the Meeting.
Shareholder Information and Questions
Shareholders who have questions about the management information circular, or require assistance with voting their shares can contact the Company’s proxy solicitation agent, Laurel Hill Advisory Group:
Laurel Hill Advisory Group
North America Toll Free: 1-877-452-7184
Outside North America: 1-416-304-0211
About ProMIS Neurosciences
ProMIS Neurosciences, Inc. is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). The Company’s proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform—ProMIS™ and Collective Coordinates—to predict novel targets, known as Disease Specific Epitopes, on the molecular surface of misfolded proteins. Using this unique approach, the Company is developing novel antibody therapeutics for AD, ALS and PD. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.
For further information about ProMIS Neurosciences, please consult the Company’s website at: www.promisneurosciences.com.
For Investor Relations please
contact: Alpine Equity Advisors
Nicholas Rigopulos, President
Tel. 617 901-0785
The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "anticipates", "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed", "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur including but not limited to statements related to the intent of the Company to pursue a potential listing of the Company’s Common Shares on an exchange in the United States, the Company’s ability to access capital improving as a result of a listing on a stock exchange in the United States, the additional benefits of a share consolidation and the Company obtaining the necessary regulatory approvals and satisfying the other requirements to file an IND and commence its clinical trials related to its lead program PMN310 soon thereafter.
Readersarecautionedthatforward-lookingstatementsarebasedoncertainassumptionsandaresubject to known and unknown risks and uncertainties (both general and specific) that contribute to the possibility that the future events or circumstances contemplated by such forward-looking information will not occur. Such risks and uncertainties with respect to the forward-looking statements contained in this news release include, but are not limited to, the Company obtaining shareholder and Toronto Stock Exchange approval for a consolidation of its Common Shares, the Company’s ability to generally meet the quantitative and qualitative requirements to list its Common Shares on a stock exchange in the United States, the trading volumes in the Company’s Common Shares increasing as a result of a listing on a stock exchange in the United States, the Company’s ability to access capital improving as a result of a listing on a stock exchange in the United States, and the Company obtaining the necessary regulatory approvals and satisfying the other requirements to file an IND and commence its clinical trials related to its lead program PMN310 soon thereafter. Readers should also refer to the risk factors set forth in the Company’s continuous disclosure documents available at SEDAR (www.sedar.com). There can be no assurance that the plans, intentions or expectations upon which forward-looking statements are based will be realized. Actual results may differ, and the difference may be material and adverse to the Company and its shareholders. Therefore, readers should not place undue reliance upon such forward- looking statements. The Company does not intend, and does not assume any obligation, to update these forward-lookingstatementsinordertoreflecteventsorcircumstancesthatmayariseafterthedateofthis newsreleaseexceptasrequiredbyapplicablelaworregulatoryrequirements.To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
TGS Share Repurchase2.12.2021 10:57:49 CET | Press release
Oslo, Norway (02 December 2021) – On period from 25 November 2021 to 01 December 2021, TGS ASA (TGS) purchased 67,328 own shares on the Oslo Stock Exchange at an average price of NOK 85.1890 per share. Following the purchase TGS owns 1,226,303 shares, representing 1.044% of the total outstanding shares. The shares were purchased in connection with the share repurchase announced on 11 February 2021. Overview of transactionsDateAggregated daily volume (number of shares)Weighted average share price per day (NOK)Total daily transaction value (NOK)25-Nov-2110,87888.9977968,11726-Nov-2120,00084.97931,699,58629-Nov-212,00084.2400168,48030-Nov-2120,00084.16361,683,2721-Dec-2114,45084.16241,216,147Previously disclosed buy-backs under the program (accumulated)1,143,975105.5774120,777,940Accumulated under the buy-back program1,211,303104.4442126,513,541The issuer's holding of own shares:Following the completion of the above transactions, TGS owns a total of 1,226,303 own shares, corresponding to
AB Linas Agro Group investors calendar for the 20222.12.2021 10:41:10 CET | Press release
A list of key information disclosure dates in 2022: February 28, 2022Interim half-year unaudited report for FY 2021/2022.March 1, 2022Investor Conference Webinar to introduce unaudited financial and activity results for the half-year of FY 2021/2022.May 31, 2022Interim unaudited report for 9 months of FY 2021/2022.June 1, 2022Investor Conference Webinar to introduce unaudited financial and activity results for 9 months of FY 2021/2022.August 31, 2022Interim unaudited report for 12 months of FY 2021/2022.September 2, 2022Investor Conference Webinar to introduce unaudited financial and activity results for 12 months of FY 2021/2022.Week 40 (Oct 3-7, 2022)Notice on Annual General Meeting of shareholders.Week 43 (Oct 24-28, 2022) Resolutions of the Annual General Meeting of shareholders and Annual audited results for FY 2021/2022.November 30, 2022Interim unaudited report for 3 months of 2022/2023 financial year.December 1, 2022Investor Conference Webinar to introduce unaudited financial an
RESULT OF RIKSBANK REVERSED AUCTIONS SEK COVERED BONDS2.12.2021 10:10:00 CET | Press release
RESULT OF RIKSBANK REVERSED AUCTIONS SEK COVERED BONDS Auction date2021-12-02Loan194Coupon1.00 %ISIN-codeSE0012142206Maturity2024-09-18 Tendered volume, SEK mln400 +/- 200 Volume offered, SEK mln1,600 Volume bought, SEK mln600 Number of bids5 Number of accepted bids3 Average yield0.230 %Lowest accepted yield0.226 %Highest yield0.234 %% accepted at lowest yield 50.00 Auction date2021-12-02Loan1594Coupon2.00 %ISIN-codeSE0011062892Maturity2028-09-01 Tendered volume, SEK mln1,300 +/- 650 Volume offered, SEK mln2,600 Volume bought, SEK mln50 Number of bids5 Number of accepted bids1 Average yield0.857 %Lowest accepted yield0.857 %Highest yield0.857 %% accepted at lowest yield 100.00 Auction date2021-12-02Loan146Coupon0.50 %ISIN-codeSE0013381571Maturity2025-06-11 Tendered volume, SEK mln600 +/- 300 Volume offered, SEK mln1,700 Volume bought, SEK mln900 Number of bids3 Number of accepted bids2 Average yield0.395 %Lowest accepted yield0.395 %Highest yield0.395 %% accepted at lowest yield 81.82
Incap Corporation: Incap’s schedule for financial reporting in the year 20222.12.2021 08:30:00 CET | Press release
Incap Corporation: Incap’s schedule for financial reporting in the year 2022 Incap Corporation will publish the following financial reports in 2022: financial statements release for 2021 on Thursday, 24 February 2022 annual report for 2021 during week 13/2022 (week commencing on 28 March 2022) business review for January-March 2022 on Wednesday, 27 April 2022 half-year report for January-June 2022 on Thursday, 28 July 2022 business review for January-September 2022 on Thursday, 27 October 2022. The annual report includes the report of the Board of the Directors, the financial statements of the Group and the parent company as well as the auditor’s report for the financial period 1 January–31 December 2021. At the same time, the company will also publish the corporate responsibility report, the report on Corporate Governance as well as the report on remuneration. Incap’s Annual General Meeting is scheduled to be held on Friday, 29 April 2022 in Helsinki. A shareholder has the right to ha
Strategic Business Update - Acquisition of Precise-ITC and completion of major milestones for China Product Partnership2.12.2021 08:00:00 CET | Press release
LONDON and TORONTO, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Alphawave IP (LN:AWE), a global leader in high-speed connectivity for the world’s technology infrastructure, is pleased to announce the acquisition of Precise-ITC and the completion of significant milestones for the China Product Partnership (“CPP”). Key highlights Alphawave IP has agreed to acquire Precise-ITC, Inc., an emerging leader in the Ethernet and Optical Transport Network (OTN) communications connectivity IP space. Alphawave IP has also completed all CPP implementation milestones and CPP, now incorporated as WiseWave Technology Co., Ltd (“WiseWave”), has been funded and will receive its first IP delivery from Alphawave IP in December 2021, as planned. WiseWave was founded as a Chinese semiconductor device company focused on the mainland Chinese market. In addition, Alphawave IP has completed the consolidation of its VeriSilicon reseller relationship with WiseWave to provide one interface to customers in China, in line with
Terranet Capital Markets Day on the 6th of December is around the corner2.12.2021 08:00:00 CET | Press release
On the 6th of December Terranet welcomes you to an exclusive day where you will be exposed to some of the avant garde brains in the Terranet ecosystem and the global automotive industry. At this event Terranet will reveal the latest progress and milestone achievements and showcase some insights behind the industry-collaborations. Please ensure you reserve your seat for the event in Stockholm here, only limited seats availiable: https://bit.ly/3mflryl Each presentation will be broadcasted and distributed live digitally. Sign up here: https://bit.ly/3B308UP Please find the updated schedule below: The schedule of the day (CET): 10:10 - 10.15 Ronja Koepke, Moderator 10:15 - 10.25 Par-Olof Johannesson, CEO Terranet 10:25 - 10:30 Ronja Koepke, Moderator 10:30 - 10.45 Jan Glevén, Head of Insight Mangold Fondkommission. 10:45 - 10.50 Ronja Koepke, Moderator 10:50 - 11:05 Panel discussion Jan Glevén, Head of Insight Mangold Fondkommission & Hampus Engellau, Handelsbanken Capital Markets 11.05 -
Systemairs rapport för det andra kvartalet presenteras den 9 december2.12.2021 08:00:00 CET | Pressemelding
Pressmeddelande 2 december 2021 Systemair ABs (NASDAQ OMX Stockholm: SYSR) delårsrapport Q2 för räkenskapsåret 2021/22 kommer att offentliggöras kl. 08:00 CET den 9 december 2021. En telefonkonferens arrangeras kl. 09:00 CET den 9 december 2021. Rapporten presenteras av Roland Kasper, CEO, samt Anders Ulff, CFO. För att delta i telefonkonferensen: Ring 0200-883 685 alt. internationellt +46 8 566 426 51 och uppge kod 50215855# minuter före start. Presentationen publiceras på group.systemair.com För ytterligare information kontakta: Roland Kasper, CEO, + 46 73 094 40 13 Anders Ulff, CFO, + 46 70 577 40 09 Systemair AB, 739 30 Skinnskatteberg, 0222-440 00, www.systemair.com Systemair i korthet Systemair är ett ledande ventilationsföretag med verksamhet i 54 länder i Europa, Nordamerika, Sydamerika, Mellanöstern, Asien, Australien och Afrika. Bolaget omsatte 8,5 miljarder kronor räkenskapsåret 2020/21 och har cirka 6 400 anställda. Sedan grundandet av Systemair 1974 har bolaget uppvisat po